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Context—There has been rapid adoption of newer radiation treatments such as
intensitymodulated radiation therapy (IMRT) and proton therapy despite greater cost and limited
demonstrated benefit compared with previous technologies.
Objective—To determine the comparative morbidity and disease control of IMRT, proton
therapy, and conformal radiation therapy for primary prostate cancer treatment.
Design, Setting, and Patients—Population-based study using Surveillance, Epidemiology,
and End Results–Medicare-linked data from 2000 through 2009 for patients with nonmetastatic
prostate cancer.
Main Outcome Measures—Rates of gastrointestinal and urinary morbidity, erectile
dysfunction, hip fractures, and additional cancer therapy.
Results—Use of IMRT vs conformal radiation therapy increased from 0.15% in 2000 to 95.9%
in 2008. In propensity score–adjusted analyses (N=12 976), men who received IMRT vs
conformal radiation therapy were less likely to receive a diagnosis of gastrointestinal morbidities
(absolute risk, 13.4 vs 14.7 per 100 person-years; relative risk [RR], 0.91; 95% CI, 0.86–0.96) and
hip fractures (absolute risk, 0.8 vs 1.0 per 100 person-years; RR, 0.78; 95% CI, 0.65–0.93) but
more likely to receive a diagnosis of erectile dysfunction (absolute risk, 5.9 vs 5.3 per 100 person-
years; RR, 1.12; 95% CI, 1.03–1.20). Intensitymodulated radiation therapy patients were less
likely to receive additional cancer therapy (absolute risk, 2.5 vs 3.1 per 100 person-years; RR,
0.81; 95% CI, 0.73–0.89). In a propensity score–matched comparison between IMRT and proton
therapy (n=1368), IMRT patients had a lower rate of gastrointestinal morbidity (absolute risk, 12.2
vs 17.8 per 100 person-years; RR, 0.66; 95% CI, 0.55–0.79). There were no significant differences
in rates of other morbidities or additional therapies between IMRT and proton therapy.
Conclusions—Among patients with nonmetastatic prostate cancer, the use of IMRT compared
with conformal radiation therapy was associated with less gastrointestinal morbidity and fewer hip
fractures but more erectile dysfunction; IMRT compared with proton therapy was associated with
less gastrointestinal morbidity.
Prostate cancer is the most common malignancy in men, with more than 200 000 diagnoses
and 30 000 deaths per year.1 Recent advances in technology have led to costlier treatments
such as minimally invasive radical prostatectomy, intensity-modulated radiation therapy
(IMRT), and proton therapy. The adoption of these technologies resulted in a $350 million
increase in health care expenditures in 2005 alone.2 The Institute of Medicine, Agency for
Healthcare Research and Quality, Secretary of the Department of Health and Human
Services, and others have called for comparative effectiveness research of localized prostate
cancer treatments,3–5 which is especially relevant for radiation therapy, for which IMRT has
gradually replaced the older technique of con-formal radiation therapy during the past 10
years. More recently, there has been a substantial increase in the number of proton facilities
built, and direct-to-consumer advertising is likely to lead to an increase in its use.6–8 The
clinical benefit from these newer treatments is un-proven, and comparative effectiveness
research examining different radiation techniques is lacking. Given these trends in use,
multiple recent reports have specifically called for research on proton therapy.9
The objective of this study was to examine the comparative morbidity and disease control
outcomes after different radiation techniques in a recent cohort of prostate cancer patients
with the Surveillance, Epidemiology, and End Results (SEER)–Medicare-linked database.
Specifically, we compared IMRT, which has been rapidly adopted and is currently the most
commonly used technique, with the older conformal radiation therapy. We further compared
proton therapy, whose use is increasing,6 with IMRT.
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Surveillance, Epidemiology, and End Results data are composed of 16 population-based
cancer registries representing approximately 26% of the US population. SEER-Medicare
links the registry data to Medicare administrative and health care claims data, which include
97% of US residents aged 65 years and older and has been documented extensively.10
University of North Carolina institutional review board approval was waived.
Study Cohorts
According to SEER-Medicare data, 251 787 patients received a diagnosis of prostate cancer
between 2000 and 2007; had no additional cancers, meta-static disease, or disease diagnosis
at autopsy; and had month and year of diagnosis in the database. To allow assessment of
baseline comorbidity, the patient population was further restricted to men with at least 1 year
of claims data before diagnosis.11 To ensure complete capture of health services, we
excluded men who were enrolled in a health maintenance organization within 1 year of
diagnosis or not enrolled in both Medicare Part A and Part B for the study duration, which
resulted in a cohort of 108 756 patients. A sensitivity analysis excluded patients who had
any health maintenance organization enrollment for the study duration and demonstrated
similar results (eAppendix, available at http://www.jama.com).
Using Current Procedural Terminology/Healthcare Common Procedure Coding System
procedure codes, we identified 15 963 men who received radiation as primary treatment
within 1 year of diagnosis (eAppendix). Patients who received radiation in combination with
brachytherapy or prostatectomy were excluded. For the IMRT vs conformal radiation
therapy comparison, we observed a large shift in use of these techniques during the study
period (eFigure). To enable propensity score weighting in the 2 treatment groups, analysis
was restricted to 12 976 men who received treatment between 2002 and 2006 to maximize
the overlap in baseline characteristics: 6666 treated with IMRT and 6310 with conformal
radiation therapy. Median follow-up for this comparison was 44 months for IMRT (range,
0.1–91.5 months) and 64 months for conformal radiation therapy (range, 0–91.7 months).
For the proton therapy vs IMRT comparison, we identified 684 men treated with proton
therapy from 2002 to 2007. Because few institutions offered proton therapy, there was lack
of overlap in baseline characteristics between proton therapy and IMRT patients largely
because of 2 higher-level variables: SEER region and institutional affiliation with the
Radiation Therapy Oncology Group. Therefore, we used propensity score matching to
compare proton therapy with IMRT patients. Median follow-up for this comparison was 46
months for IMRT (range, 0.4–88.3 months) and 50 months for proton therapy (range, 0.3–
90.2 months).
Outcomes
Morbidity outcomes included conditions associated with radiation therapy for prostate
cancer: gastrointestinal morbidity, urinary incontinence, non-incontinence urinary
morbidity, sexual dysfunction, and hip fractures.12–16 Diagnoses and procedures in each
morbidity category were counted as separate outcomes. Because the goal of this study was
to examine long-term morbidity, we excluded person-time and diagnoses and procedures
that occurred within 1 year of radiation therapy; acute radiation therapy–related morbidity
commonly resolves and does not become long-term morbidity.12
Consistent with previous studies, we identified men requiring additional cancer therapy after
radiation therapy as an indicator of disease recurrence.17–19 Because radiation therapy is
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commonly used in combination with brachytherapy20 and sometimes as neoadjuvant
treatment for planned prostatectomy,21 we defined additional cancer treatment as that
occurring 9 months or more after initiation of radiation therapy. Furthermore, for patients
who received radiation therapy concurrently with androgen deprivation therapy, additional
treatment was defined as cessation of all treatment for 9 months or more, followed by
reinitiation of androgen deprivation therapy or another salvage treatment.
Survival was not examined because death caused by prostate cancer is minimal within 5
years of diagnosis and not expected to be significantly different by radiation therapy
technique within this period.1
Control Variables
The SEER registry provided patient-level demographic variables, including race, age at
diagnosis, and marital status; census tract measures of income and education; SEER region;
and population density (urban vs rural). Medicare claims data provided information on
treatment dates, enrollment, and institutional affiliation with the Radiation Therapy
Oncology Group, a radiation-specific clinical trials cooperative group. Radiation Therapy
Oncology Group affiliation was used in propensity score weighting for the IMRT vs
conformal radiation therapy comparison.
Baseline diagnoses of diabetes and conditions associated with the use of anticoagulation
(atrial fibrillation and valvular disease) were determined by using claims within the year
before radiation therapy (eAppendix); both have been shown to increase the morbidity risk
from radiation therapy.22–24 Use of androgen deprivation therapy in conjunction with
radiation therapy was included as a covariate because of its potential effects on both disease
control and erectile dysfunction.25
Statistical Analysis
For the IMRT vs conformal radiation therapy comparisons, we used propensity score
weighting to adjust for potentially important baseline characteristics. We used logistic
regression to estimate the probability of receiving IMRT vs conformal radiation therapy (the
propensity score) as a function of relevant covariates (Table 1 and 2). We evaluated the
distributions of propensity scores by treatment group to check for sizeable overlap
demonstrating that the groups are comparable. A propensity score weight was calculated as
the inverse of the propensity for the treatment received and then stabilized, reflecting the
sample size for each treatment group.
For each outcome, we calculated number of events per 100 person-years of follow-up to be
consistent with existing literature.3 We calculated the probability of additional treatment
after propensity score weighting with the Kaplan-Meier method and used log-rank statistics
to assess for potential difference in patients treated with IMRT vs conformal radiation
therapy. Follow-up time was determined from the start of follow-up (12 months after the
start of radiation therapy for morbidity and 9 months for additional therapies) until an event
or censoring at the end of the study (December 31, 2009).
For the proton therapy vs IMRT comparisons, we applied propensity score matching to
balance the 2 groups and calculated propensity score–matched rates for each outcome.
Because of unequal distribution of proton patients across institutional-level variables, we
performed sensitivity analysis with the Radiation Therapy Oncology Group affiliation as an
instrumental variable to assess potential unmeasured confounding. Of all measured
covariates, this affiliation was the strongest predictor of treatment receipt and was
considered a priori as a possible instrument. In sensitivity analysis, we applied methods to
test for the strength of the affiliation as an instrument among subgroups of the population
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and found that overall, the Radiation Therapy Oncology Group qualifies as a preference-
based instrument.26 To maintain comparability between our other rate models, a modified 2-
stage least-squares approach was applied.27
Statistical significance was set at .05; all tests were 2-tailed and no adjustment was made for
multiple comparisons. Analyses were performed with SAS version 9.2.
RESULTS
Among the patients undergoing primary radiation therapy for nonmetastatic prostate cancer,
use of IMRT vs conformal radiation therapy increased from 0.15% in 2000 to 95.9% in 2008
(eFigure). After propensity score weighting, baseline characteristics among conformal
radiation therapy and IMRT patients were balanced, except for small residual differences in
year of treatment (Table 1 and Table 2).
Unadjusted and propensity score–adjusted outcomes for IMRT vs conformal radiation
therapy are presented in Table 3. In the adjusted analysis, men treated with IMRT were less
likely to receive a diagnosis of gastrointestinal morbidity (13.4 for IMRT vs 14.7 for
conformal radiation therapy per 100 person-years; relative risk [RR], 0.91; 95% CI, 0.86–
0.96; P<.001) and hip fracture (0.8 for IMRT vs 1.0; RR, 0.78; 95% CI, 0.65–0.93; P = .006)
but more likely to receive a diagnosis of erectile dysfunction (5.9 for IMRT vs 5.3; RR,
1.12; 95% CI, 1.03–1.20;P=.006). Furthermore, IMRT patients were less likely to receive
additional cancer therapy (2.5 for IMRT vs 3.1; RR, 0.81; 95% CI, 0.73–0.89; P<.001)
(Table 3, Figure 1).
For the proton therapy vs IMRT comparison, propensity-matched baseline characteristics are
presented in Table 4 and 5. Proton therapy patients had slightly less frequent baseline
anticoagulation use. For morbidity and additional therapy outcomes, results from propensity
score– matched and instrumental variable analyses were consistent (Table 4 and Table 5).
There was no significant difference in proton therapy– vs IMRT-treated patients in urinary
nonincontinence or incontinence diagnoses or procedures, erectile dysfunction, or hip
fractures. The low hip fracture incidence precluded calculation of rate ratios in the
propensity score–matched model. In both models, proton therapy– treated patients were
more likely to receive a diagnosis of gastrointestinal morbidity and undergo gastrointestinal
procedures. Rates of additional cancer therapy were no different between the 2 groups
(Table 6, Figure 2).
COMMENT
Comparative effectiveness research in localized prostate cancer treatments is needed
because of the large number of men with this disease and the continued trend of a rapid
increase in use of newer and costlier treatments with un-proven clinical benefit. The Institute
of Medicine included localized prostate cancer as a “first quartile” priority topic in its top
100 topics for comparative effectiveness research.3 Although the theoretic rationale for the
new treatments such as minimally invasive prostatectomy and IMRT is convincing, studies
directly comparing the outcomes of newer vs older treatments are lacking. A recent SEER-
Medicare study that reported mixed results when comparing minimally invasive
prostatectomy vs the older open prostatectomy technique demonstrated that theoretic
advantages for newer treatments may not necessarily translate into a clinical benefit.18
Radiation treatment can cause damage to organs surrounding the prostate, leading to long-
term gastrointestinal and urinary morbidity, erectile dysfunction, and hip fractures. In the
past 10 years, data have demonstrated that the risk of long-term morbidity is directly
associated with the radiation dose received by each organ.28–31 These data led to the
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development of dose guidelines for the bowel and rectum, femoral heads, and bladder,
which were widely adopted and are now a standard part of radiation treatment planning.
Dose guidelines to minimize erectile dysfunction are not widely used because no organ or
structure has been identified that consistently demonstrates an association between dose of
radiation to the structure and erectile dysfunction.30
Delivering a high radiation dose to the prostate while limiting doses to surrounding organs
to minimize long- term morbidity presents a significant challenge. In addition, between 2002
and 2006, 3 randomized trials were published that consistently demonstrated that higher
radiation doses (78–79 Gy) resulted in improved freedom from recurrence compared with
lower doses (68–70 Gy).32–34 However, higher doses also resulted in increased morbidity in
these patients treated with conformal radiation techniques. Because these results changed the
standard of care to “dose-escalated” radiation therapy for prostate cancer, simultaneously
minimizing doses received by surrounding organs, especially the bowel and femoral heads,
became even more difficult.
The potential advantage of IMRT compared with conformal radiation therapy is its ability to
deliver high radiation doses to the prostate while minimizing doses to surrounding organs.35
However, the clinical benefit of this approach is largely untested. In a retrospective, single-
institution study, Zelefsky et al12 reported that the 10-year rate of gastrointestinal morbidity
was lower for IMRT-treated patients (5%) compared with those who received conformal
radiation therapy (13%), despite a higher dose to the prostate prescribed among the IMRT
patients. To our knowledge, no study has compared the nongastrointestinal morbidity and
disease control outcomes between conformal radiation therapy and IMRT. Yet, as we have
demonstrated, there has been an almost complete adoption of IMRT for prostate cancer.
From 2000 to 2008, IMRT use increased from 0.15% to 95.9%, and the timing is consistent
with a surge in the use of IMRT to deliver dose-escalated treatment after publication of the 3
aforementioned trials.32,36,37 Despite a higher dose administered, patients who received
IMRT compared with conformal radiation therapy were less likely to receive a diagnosis of
gastrointestinal morbidity and hip fracture. Because bowel and femoral head dose
limitations are routinely considered in radiation planning, the improved ability of IMRT to
minimize doses to these organs is a likely explanation. Another possibility is an
improvement in physician understanding of and attention to organ dose guidelines, which
may have paralleled the adoption of IMRT, resulting in better treatment plans that may have
also been achievable with conformal radiation therapy, if such constraints were addressed.
No difference was observed in the rates of urinary morbidity. Erectile dysfunction was
diagnosed more frequently in IMRT patients. Because the relevant anatomic structures
associated with radiation-induced erectile dysfunction have not yet been identified, it is
possible that increased erectile dysfunction from IMRT is due to delivery of dose-escalated
treatment, resulting in a higher unintentional dose administered to these structures. These
results are similar to those reported from a study of comparable design, which used an older
patient cohort and had shorter follow-up.15
Patients receiving IMRT were less likely than those receiving conformal radiation therapy to
undergo additional cancer treatments, which is consistent with the use of IMRT to deliver
dose-escalated treatment, resulting in improved cancer control, as demonstrated by the
randomized trials. Taken together, these results suggest that IMRT facilitated radiation dose
escalation without compromising acceptable long-term morbidity.
Proton therapy is a high-profile, high-cost prostate cancer treatment. Since 2007, multiple
proton facilities have been built, and direct-to-consumer advertising is likely to lead to a
substantial increase in use.6–8 The potential advantage of proton therapy compared with
Sheets et al. Page 6













IMRT is unclear. Radiation planning studies demonstrated that proton therapy relative to
IMRT may reduce the proportion of each surrounding organ that receives low doses of
radiation, which has unclear clinical significance but may be more prone to errors related to
daily patient setup and positioning, as well as organ movement during treatment.38–40
To our knowledge, this study includes the largest series of proton therapy patients. We
found no significant differences among patients treated with proton therapy vs IMRT in
morbidity or receipt of additional cancer therapy, except an association with increased
gastrointestinal morbidity in proton therapy patients. Another recent study also found higher
gastrointestinal morbidity rates in proton therapy patients relative to IMRT patients.41 One
possible explanation is the higher vulnerability of proton therapy to organ movement, which
may lead to an unintentional higher dose to the rectum compared with IMRT. Whether the
use of better image guidance reduces gastrointestinal morbidity is unknown. Overall, our
results do not clearly demonstrate a clinical benefit to support the recent increase in proton
therapy use for prostate cancer.
The strengths of our study include the use of a large, population-based cohort that reflects
treatment outcomes in the community setting. The follow-up duration is longer than that of
previous studies15,18 and may there- fore provide more stable estimates of long-term
outcomes. We adjusted for baseline morbidity and included co-variates that could influence
treatment outcomes, such as diabetes and a proxy for anticoagulation. We applied several
analytic approaches to test the stability of our effect estimates, including propensity score
weighting and matching, instrumental variable analyses, and Poisson and negative binomial
models. Effect estimates and conclusions were consistent regardless of model choice. Our
data on proton therapy are unique, and, to our knowledge, this is the first study to examine
morbidity and disease control outcomes among the 3 most commonly used radiation
techniques for prostate cancer. Because IMRT and proton therapy are relatively new
technologies, several more years of use and patient follow-up are needed to examine
comparative survival outcomes.
There are limitations to the use of SEER-Medicare data for the assessment of clinical
outcomes. Claims files are not designed to provide detailed clinical information, so the data
may be subject to misclassification. For example, morbidity diagnoses may be attributable to
reasons other than the type of radiation therapy received, and certain outcomes (such as
erectile dysfunction) may be underreported.42 However, these potential limitations should be
balanced in the different patient cohorts to allow a comparison of relative rates of morbidity.
There may also be bias in patient and physician reporting of morbidity, as well as use of
additional cancer therapies; whether this bias affects patients treated with one form of
radiation therapy more than another is unknown. An examination of our data, along with
those reported by Hu et al,18 who used SEER-Medicare data to examine the morbidity
diagnoses after prostatectomy, indicates relatively higher rates of urinary incontinence and
erectile dysfunction in prostatectomy patients and noncontinence urinary and bowel
morbidity in radiation patients. These findings are consistent with those of previous studies
reporting physician-assessed morbidity and patient-reported outcomes.43–45 Furthermore,
prostate cancer risk group was not available and can affect radiation dose and extent of
treatment, with consequent effects on morbidity. However, cohorts were balanced for tumor
grade and clinical stage. In addition, although SEER was designed to provide data
representative of the US population,10 whether our results are generalizable with respect to
choice of treatments, disease severity, and rates of outcomes requires further study.
Given the near-complete adoption of IMRT, it is unlikely that a randomized trial of IMRT
vs conformal radiation therapy could ever be performed. An IMRT vs proton therapy trial
would require many years to provide results. With the recent rapid increase in the number of
Sheets et al. Page 7













proton facilities,7 comparative data are needed. Despite limitations in SEER-Medicare data,
they represent an important data source with an established methodology for comparative
effectiveness research.18 Furthermore, SEER-Medicare data are drawn from a large
population-based sample and are therefore more likely to reflect results from treatments
widely available in the community, broadening the generalizability of results in comparison
to single-institutional studies or even clinical trials, which often have stringent patient
selection criteria.
CONCLUSIONS
Among patients with nonmetastatic prostate cancer, use of IMRT vs conformal radiation
therapy increased substantially from 2000 to 2008. Compared with conformal radiation
therapy, IMRT was associated with fewer diagnoses of gastrointestinal morbidity, hip
fractures, and additional cancer therapy but more erectile dysfunction. Proton therapy was
associated with more gastrointestinal morbidity than IMRT. This population-based study
suggests that IMRT may be associated with improved disease control without compromising
morbidity compared with conformal radiation therapy, although proton therapy does not
appear to provide additional benefit.
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